Rupee closes lower against US dollar ahead of RBI policy review
The rupee closed at 67.15 against the US dollar, down 0.06% from its previous close of 67.11
Mumbai: The Indian rupee on Tuesday closed marginally lower against the US dollar as traders turned cautious ahead of the Reserve Bank of India’s bi-monthly policy outcome.
The rupee closed at 67.15 against the US dollar, down 0.06% from its previous close of 67.11. The currency opened at 67.08 a dollar and touched a high and a low of 67.07 and 67.23, respectively.
Of the 15 economists surveyed by Mint, 11 expect the central bank to keep the repo rate—the rate at which the central bank infuses liquidity in the banking system—unchanged at 6%. Only four economists expect RBI to raise rates by 25 basis points (bps).
The 10-year bond yield ended at 7.837% from its Monday’s close of 7.876%. Bond yields and prices move in opposite directions.
So far this year, the rupee has weakened 4.83%, while foreign investors have sold $225.90 million and $4.45 billion in equity and debt markets, respectively.
Benchmark Sensex Index fell 0.31% or 108.68 points to 34,903.21. Since January, it has gained 2.4%.
Asian currencies were trading higher. South Korean won was up 0.35%, Taiwan dollar 0.19%, Thai baht 0.17%, Singapore dollar 0.1%, Philippines peso 0.09%. However, Malaysian ringgit was down 0.08%.
The dollar index, which measures the US currency’s strength against major currencies, was trading at 94.068, up 0.03% from its previous close of 94.038.
Editor's Picks »
- Millennial Money: Don’t let Instagram envy get you into debt
- Jet Airways says discussing SBI resolution plan with shareholders
- SBI puts on sale Essar Steel loan of Rs 15,431 crore
- London copper rises on weaker dollar, China stimulus hopes
- From airport closure to IPOs, how partial shutdown is upsetting US economy
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms
- Roads sector: Toll collections set to surge, but risks loom for developers